黄芪甲苷药理机制研究进展
摘要
关键词
全文:
PDF参考
[1]Zhang，J.；Wu，C. Gao，L.etal.Astragaloside IV derived from Astragalus membranaceus：A research review on the pharmacological
effects. Adv. Pharmacol. San Diego Calif.2020，87，89–112.
[2]Brouns，R.；De Deyn，P.P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg.2009，111，
483–495.
[3]Liang Y，Chen B，Liang D，etal. Pharmacological Effects of Astragaloside IV：A Review. Molecules. 2023 Aug 18；28（16）：6118.
doi：10.3390/molecules28166118. PMID：37630371；PMCID：PMC10458270.
[4]李明泽，et al."黄芪甲苷生理功能研究进展."食品工业 45.06（2024）：164-168.
[5]Zhang J，Wu C，Gao L，Du G，Qin X. Astragaloside IV derived from Astragalus membranaceus：A research review on the
pharmacological effects. Adv Pharmacol. 2020；87：89–112. doi：10.1016/bs.apha.2019.08.002
[6]关静，黄凡克，周伊璐，等.黄芪甲苷抗心力衰竭患者缺血缺氧性心肌损伤的机制研究进展[J].实用心脑肺血管病杂志，2023，
31（09）：111-114.
[7]秦合伟等。黄芪甲苷调控 miR-17-5p 与 PCSK9/VLDLR 信号通路抗动脉粥样硬化的分子机制研究."中国中药杂志 47.02
（2022）：492-498.doi：10.19540/j.cnki.cjcmm.20210918.701.
[8]Y.Luo，Q.Wan，M.Xu，etal.Nutritional preconditioning induced by astragaloside IV on isolated hearts and cardiomyocytes against
myocardial ischemia injury via improving Bcl-2-mediated mitochondrialfunctionChem.Biol.Interact.25（2019），pp.108723-108734，
10.1016/j.cbi.2019.06.036
[9]H. Huang，S.Lai，Q.Wan etal.Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the
expression of Hes1 protein
[10]Yuan H，Shi M，Wei J，etal. Integrating bioinformatics and ferroptosis to reveal the protective mechanism of Astragaloside IV on
chronic heart failure rats. Sci Rep. 2024 Sep 6；14（1）：20787. doi：10.1038/s41598-024-72011-z. PMID：39242661；PMCID：
PMC11379966.
[11]贾伟伟，罗楠，赵宇，等.黄芪甲苷调控线粒体动力学相关蛋白改善异丙肾上腺素诱导的大鼠心肌损伤[J].中国老年学杂志，
2023，43（23）：5786-5790.
[12]Tan J，Yi J，Cao X，Wang F，etal. Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases. Drug Des Devel
Ther. 2023 Jul 3；17：1963-1978. doi：10.2147/DDDT.S416091. PMID：37426627；PMCID：PMC10328396.
[13]Luo Y，Teng X，Zhang L，etal. CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial
hypertension. Nat Commun. 2019；10（1）：3551. doi：10.1038/s41467-019-11500-6.
[14]Dunham-Snary KJ，Wu D，Sykes EA，etal. Hypoxic pulmonary vasoconstriction：from Molecular Mechanisms to Medicine. Chest.
2017；151（1）：181–92. doi：10.1016/j.chest.2016.09.001
[15]Xi J，Ma Y，Liu D，etal. Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to
ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway. BMC Pulm Med. 2023 Oct 12；23（1）：386doi：10.1186/s12890-023-02660-9. PMID：37828459；PMCID：PMC10568875.
[16]Ni Y，Shi G，Yu Y，etal. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid
bronchiectasis ： A systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015 ； 28 ： 1465–1475. doi ：
10.2147/COPD.S83910
[17]Sohrabi F，Dianat M，Badavi M，etal．Gallic acid suppresses inflammation and oxidative stress through modulating Nrf2-HO-1-NF-
κB signaling pathways in elastase-induced emphysema in rats[J]． Environ Sci and Pollut Ｒes Int，2021，28（40）：56822-56834.
[18]沈三英，谈小琴.黄芪甲苷对慢性阻塞性肺疾病氧化应激的作用及其机制研究[J].中药材，2022，45（12）：2975-2981.DOI：
10.13863/j.issn1001-4454.2022.12.033.
[19]Reddel H.K.，Bateman E.D.，Schatz M.，etal. A practical guide to implementing SMART in asthma management. J. Allergy Clin.
Immunol. Pract. 2022；10（1S）：S31–S38. doi：10.1016/j.jaip.2021.10.011.
[20].Papi A.，Brightling C.，Pedersen S.E.，etal. Asthma. Lancet. 2018；391（10122）：783–800. doi：10.1016/S0140-6736（17）
33311-1.
[21]Amrani Y.，Panettieri R.A.，Ramos-Ramirez P. etal. Important lessons learned from studies on the pharmacology of glucocorticoids
in human airway smooth muscle cells：too much of a good thing may be a problem. Pharmacol. Ther. 2020；213 doi：
10.1016/j.pharmthera.2020.107589
[22]Yuan X.J.，Sun S.Q.，Wang S.C.，etal. Effects of astragaloside IV on IFN-gamma level and prolonged airway dysfunction in a murine
model of chronic asthma. Planta Med. 2011；77（4）：328–333. doi：10.1055/s-0030-1250408
[23]Ok I.S.，Kim S.H.，Kim B.K.，etal. Pinellia ternata，Citrus reticulata，and their combinational prescription inhibit eosinophil
infiltration and airway hyperresponsiveness by suppressing CCR3+ and Th2 cytokines production in the ovalbumin-induced asthma
model. Mediators Inflamm. 2009；2009 doi：10.1155/2009/413270.
[24].Jin H.，Wang L.，Li B.etal. Astragaloside IV ameliorates airway inflammation in an established murine model of asthma by inhibiting
the mTORC1 signaling pathway. Evid Based Complement Alternat Med. 2017；2017 doi：10.1155/2017/4037086. Epub 2017 Oct 25.
PMID：29234390；PMCID：PMC5676443. Evid Based Complement Alternat Med. 2017；2017：4037086. doi：10.1155/2017/4037086.
Epub 2017 Oct 25. PMID：29234390；PMCID：PMC5676443.
[25].Gu X.，Jiang D.，Wang Y.，etal. Effects of astragaloside IV on eosinophil activation induced by house dust mite allergen. Mol. Med.
Rep. 2012；6（1）：115–120. doi：10.3892/mmr.2012.869.
[26]Lee RC，Thapa B，John T. LACES and bootstraps：the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.
Transl Lung Cancer Res 2018；7：S239-42. 10.21037/tlcr.2018.09.01
[27]Lai ST，Wang Y，Peng F. Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic
reticulum stress and autophagy. J Thorac Dis. 2020 Jul；12（7）：3715-3724. doi：10.21037/jtd-20-2098. PMID：32802451；PMCID：
PMC7399439.
[28]CUI K，KOU J Q，GU J H，etal． Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and
oxidative stress[J/OL]． BMC Complement Altern Med，2014，14（12）：461．
[29]王永生，徐小雅，杨波，等． 黄芪甲苷对博莱霉素诱导的大 鼠肺纤维化的治疗作用研究[J]．现代预防医学，2012，39
（12）：3090-3092
[30]李康丽，周奕彤，李艳荣，等.黄芪甲苷治疗中枢神经系统疾病作用机制研究进展[J].中成药，2023，45（08）：2634-2641.
[31]李媛，靳晓飞，周晓红，等 . 黄芪甲苷对脑缺血/再灌注 损 伤 大 鼠 细 胞 自 噬 的 影 响[J]. 中 国 病 理 生 理 杂
志，2018，34（11）：2037-2042.
[32]LI L，GAN H，JIN H，etal. Astragaloside Ⅳ promotes microglia/macrophages M2 polarization and enhances neurogenesis and
angiogenesis through PPARγ pathway after cerebral ischemia/reperfusion injury in rats[J]. Int Immunopharmacol，2021，92（3）：
107-113.
[33]李广从，靳春晓，刘宁.黄芪甲苷对脑缺血-再灌注损伤大鼠神经的影响及作用机制[J].西北药学杂志，2024，39（03）：46-51.
[34]陈惠刚，池小锋，封娣，等.黄芪甲苷抑制 Fas/FasL 信号通路减轻创伤性脑损伤大鼠神经功能缺损和神经元凋亡[J].天津
医药，2024，52（05）：469-474.
[35]Mendelsohn AR，Larrick JW. Cellular senescence as the key intermediate in tau-mediated neurodegeneration. Rejuvenation Res.
2018；21：572–579. doi：10.1089/rej.2018.2155.
[36].Wen W，Chen J，Ding L，etal. Astragaloside exerts anti-photoaging effects in UVB-induced premature senescence of rat dermafibroblasts through enhanced autophagy. Arch Biochem Biophys. 2018；657：31–40. doi：10.1016/j.abb.2018.09.007.
[37]Chan WS，Durairajan SS，Lu JH，etal. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell
culture. Neurochem Int. 2009；55：414–422. doi：10.1016/j.neuint.2009.04.012.
[38]Xia ML，Xie XH，Ding JH，etal. Astragaloside IV inhibits astrocyte senescence：implication in Parkinson's disease. J
Neuroinflammation. 2020 Apr 6；17（1）：105. doi：10.1186/s12974-020-01791-8. PMID：32252767；PMCID：PMC7137443.
[39]孙雪莲，黄可儿，冯小权，等. 黄芪皂苷及黄芪甲苷对慢性胃黏 膜损伤大鼠胃黏膜上皮细胞超微结构的影响[J]. 中药药
理与 临床，2011，27（2）：75-78.
[40]QIN S，HUANG K，FANG Z，etal. The effect of Astragaloside IV on ethanol-induced gastric mucosal injury in rats：involvement of
inflammation[J]. Int Immunopharmacol，2017，52：211-217.
[41]李建芝，刁云辉. 黄芪甲苷减轻实验性胃溃疡大鼠胃黏膜损伤 [J]. 基础医学与临床，2016，36（8）：1147-1149
[42]江晓涛，杨泽虹，王姝烨，等.黄芪甲苷调控 JAK2/STAT3/CXCL12 信号通路抑制炎症细胞浸润改善小鼠胃炎的机制研究[J].
广州中医药大学学报，2024，41（02）：447-456.DOI：10.13359/j.cnki.gzxbtcm.2024.02.028.
[43]Cai Z，Liu J，Bian H，etal. Astragaloside IV ameliorates necrotizing enterocolitis by attenuating oxidative stress and suppressing
inflammation via the vitamin D3-upregulated protein 1/NF-κB signaling pathway. Exp Ther Med. 2016 Oct；12（4）：2702-2708. doi：
10.3892/etm.2016.3629. Epub 2016 Aug 30. PMID：27698775；PMCID：PMC5038370.
[44]Cai T ， Zhang C ， Zhao Z ， etal. The gastric mucosal protective effects of astragaloside IV in mnng-induced
GPLrats.BiomedPharmacother. 2018 Aug；104：291-299. doi：10.1016/j.biopha.2018.04.013. Epub 2018 May 25. PMID：29775897.
[45]Wang ZF，Ma DG，Zhu Z，etal. Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts. World J
Gastroenterol. 2017 Dec 28；23（48）：8512-8525. doi：10.3748/wjg.v23.i48.8512. PMID：29358859；PMCID：PMC5752711.
[46]Zhong Y，Liu W，Xiong Y，etal. Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells.
Phytomedicine. 2022 Sep；104：154287. doi：10.1016/j.phymed.2022.154287. Epub 2022 Jun 19. PMID：35752072.
[47]Li X，Wang X，Han C，etal. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative
stressmediated p38 MAPK pathway. Free Radic Biol Med，2013，60：168-176
[48]刘丽，周宇，李双杰.黄芪甲苷对急性肝衰竭小鼠抗氧化、抗凋亡机制探讨[J].中国中西医结合杂志，2023，43（06）：722-728.
[49]Li Y，Yang X，Li X，etal. Astragaloside IV and cycloastragenol promote liver regeneration through regulation of hepatic oxidative
homeostasis and glucose/lipid metabolism. Phytomedicine. 2024 Dec；135：156165. doi：10.1016/j.phymed.2024.156165. Epub 2024
Oct 20. PMID：39461202.
[50]胡啸，刘盖.基于 HMGB1-TLR4 信号通路探讨黄芩甲苷对 DDC 诱导胆汁淤积性肝病小鼠的保护作用研究[J].现代医学与健
康研究电子杂志，2022，6（17）：58-62.
[51]白雪，陆璐，刘振权，等.黄芪甲苷抗二甲基亚硝胺诱导肝纤维化大鼠效应研究[J].湖南中医药大学学报，2020，40（01）：
22-27.
[52]H. Guo，A. Cao，S. Chu，etal.Astragaloside IV attenuates podocyte apoptosis mediated by endoplasmic reticulum stress through
upregulating sarco/endoplasmic reticulum Ca（2+）-ATPase 2 expression in diabetic nephropathy
[53]Shen Q，Fang J，Guo H，etal. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by
up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease. Free Radic Biol Med. 2023 Jul ； 203 ： 45-57. doi ：
10.1016/j.freeradbiomed.2023.03.022. Epub 2023 Apr 6. PMID：37030337.
[54].Rabb H，O’Meara YM，Maderna P，etal. Leukocytes，cell adhesion molecules and ischemic acute renal failure. Kidney Int. 1997；
51：1463–1468. doi：10.1038/ki.1997.200.
[55]Sheridan AM，Bonventre JV. Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol
Hypertens. 2015；9：427–434. doi：10.1097/00041552-200007000-00015.
[56]Xin Y，Li G，Liu H，etal. AS-IV protects against kidney IRI through inhibition of NF-κB activity and PUMA upregulation. Int J
Clin Exp Med. 2015 Oct 15；8（10）：18293-301. PMID：26770431；PMCID：PMC4694331.
[57]何自育，杨育红，王洪新.黄芪甲苷对肾性高血压大鼠肾脏的保护作用及机制研究[J].中药新药与临床药理，2014，25（04）：
446-450.
作者简介：段文静（1995-）女，汉族，佳木斯市，住院医师，儿科专业硕士，研究方向黄芪甲苷对新生儿 HIBD 作用机制
研究进展；
*通讯作者：王显鹤（1966-），女，汉族，主任医师，研究生，专业方向新生儿缺氧缺血性脑病。
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。